HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 139-149

  Menéndez Arias, Luis ^a   Betancor, Gilberto ^a   Matamoros, Tania ^a  

^a CSIC   (Spain)

Author keywords

Drug resistance; HIV; Non nucleoside RT inhibitors; Reverse transcriptase

Indexed keywords

DELAVIRDINE; DNA; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBONUCLEASE H; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CRYSTAL STRUCTURE; DNA STRAND; DRUG BINDING; ENZYME ACTIVITY; ENZYME STRUCTURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; GENETIC ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION, MISSENSE; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80054865518     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.020     Document Type: Review

References (110)

1. Abbondanzieri E.A., Bokinsky G., Rausch J.W., Zhang J.X., Le Grice S.F.J., Zhuang X. Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 2008, 453:184-189.
2. Ahgren C., Backro K., Bell F.W., Cantrell A.S., Clemens M., Colacino J.M., Deeter J.B., Engelhardt J.A., Hogberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., Kasher J.S., Kinnick M.D., Lind P., Lopez C., Morin J.M., Muesing M.A., Noreen R., Oberg B., Paget C.J., Palkowitz J.A., Parrish C.A., Pranc P., Rippy M.K., Rydergard C., Sahlberg C., Swanson S., Ternansky R.J., Unge T., Vasileff R.T., Vrang L., West S.J., Zhang H., Zhou X.-X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39:1329-1335.
3. Amiel C., Desire N., Schneider V., Delphin N., Race E., Clavel F., Piolot T., Dam E., Rozenbaum W., Nicolas J.C. A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005, 19:1922-1924.
4. Andries K., Azijn H., Thielemans T., Ludovici D., Kukla M., Heeres J., Janssen P., De Corte B., Vingerhoets J., Pauwels R., de Béthune M.-P. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48:4680-4686.
5. Archer R.H., Dykes C., Gerondelis P., Lloyd A., Fay P., Reichman R.C., Bambara R.A., Demeter L.M. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 2000, 74:8390-8401.
6. Azijn H., Tirry I., Vingerhoets J., de Béthune M.-P., Kraus G., Boven K., Jochmans D., Van Craenenbroeck E., Picchio G., Rimsky L.T. TMC278, a next generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 2010, 54:718-727.
7. Bacheler L., Jeffrey S., Hanna G., D'Aquila R., Wallace L., Logue K., Cordova B., Hertogs K., Larder B., Buckery R., Baker D., Gallagher K., Scarnati H., Tritch R., Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 2001, 75:4999-5008.
8. Balzarini J., Karlsson A., Pérez-Pérez M.J., Camarasa M.J., Tarpley W.G., De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 1993, 67:5353-5359.
9. Balzarini J., Karlsson A., Meichsner C., Paessens A., Riess G., De Clercq E., Kleim J.P. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 1994, 68:7986-7992.
10. Balzarini J., Karlsson A., Sardana V.V., Emini E.A., Camarasa M.J., De Clercq E. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C→C181I)RT HIV-1 mutants. Proc. Natl Acad. Sci. USA 1994, 91:6599-6603.
11. Balzarini J., Pelemans H., Aquaro S., Perno C.F., Witvrouw M., Schols D., De Clercq E., Karlsson A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 1996, 50:394-401.
12. Balzarini J., Pelemans H., Pérez-Pérez M.J., San-Félix A., Camarasa M.J., De Clercq E., Karlsson A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine. Mol. Pharmacol. 1996, 49:882-890.
13. Balzarini J., De Clercq E., Carbonez A., Burt V., Kleim J.P. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retroviruses 2000, 16:517-528.
14. Barreca M.L., Rao A., De Luca L., Iraci N., Monforte A.M., Maga G., De Clercq E., Pannecouque C., Balzarini J., Chimirri A. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg. Med. Chem. Lett. 2007, 17:1956-1960.
15. Biondi M.J., Beilhartz G.L., McCormick S., Götte M. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation. J. Biol. Chem. 2010, 285:26966-26975.
16. Braz V.A., Holladay L.A., Barkley M.D. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. Biochemistry 2010, 49:601-610.
17. Brehm J.H., Mellors J.W., Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008, 47:14020-14027.
18. Brenner B., Turner D., Oliveira M., Moisi D., Detorio M., Carobene M., Marlink R.G., Schapiro J., Roger M., Wainberg M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:F1-F5.
19. Buckheit R.W., Fliakas-Boltz V., Yeagy-Bargo S., Weislow O., Mayers D.L., Boyer P.L., Hughes S.H., Pan B.C., Chu S.H., Bader J.P. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 1995, 210:186-193.
20. Buckheit R.W., Kinjerski T.L., Fliakas-Boltz V., Russell J.D., Stup T.L., Pallansch L.A., Brouwer W.G., Dao D.C., Harrison W.A., Schultz R.J., Bader J.P., Yang S.S. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 1995, 39:2718-2727.
21. Cane P.A., Green H., Fearnhill E., Dunn D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007, 21:447-455.
22. Chamberlain P.P., Ren J., Nichols C.E., Douglas L., Lennerstrand J., Larder B.A., Stuart D.I., Stammers D.K. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol. 2002, 76:10015-10019.
23. Chan J.H., Hong J.S., Hunter R.N., Orr G.F., Cowan J.R., Sherman D.B., Sparks S.M., Reitter B.E., Andrews C.W., Hazen R.J., St Clair M., Boone L.R., Ferris R.G., Creech K.L., Roberts G.B., Short S.A., Weaver K., Ott R.J., Ren J., Hopkins A., Stuart D.I., Stammers D.K. 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 2001, 44:1866-1882.
24. Chiang C.C., Wang S.M., Tseng Y.T., Huang K.J., Wang C.T. Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production. Virology 2009, 383:261-270.
25. Cohen C.J., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237. on behalf of the THRIVE study group.
26. Das K., Clark A.D., Lewi P.J., Heeres J., De Jonge M.R., Koymans L.M., Vinkers H.M., Daeyaert F., Ludovici D.W., Kukla M.J., De Corte B., Kavash R.W., Ho C.Y., Ye H., Lichtenstein M.A., Andries K., Pauwels R., De Béthune M.P., Boyer P.L., Clark P., Hughes S.H., Janssen P.A., Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47:2550-2560.
27. Das K., Bauman J.D., Clark A.D., Frenkel Y.V., Lewi P.J., Shatkin A.J., Hughes S.H., Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistant mutations. Proc. Natl. Acad. Sci. USA 2008, 105:1466-1471.
28. Delviks-Frankenberry K.A., Nikolenko G.N., Boyer P.L., Hughes S.H., Coffin J.M., Jere A., Pathak V.K. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. USA 2008, 105:10943-10948.
29. Delviks-Frankenberry K.A., Nikolenko G.N., Pathak V.K. The " connection" between HIV drug resistance and RNase H. Viruses 2010, 2:1476-1503.
30. Demeter L.M., Meehan P.M., Morse G., Gerondelis P., Dexter A., Berrios L., Cox S., Freimuth W., Reichman R.C. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 14:136-144.
31. Dueweke T.J., Pushkarskaya T., Poppe S.M., Swaney S.M., Zhao J.Q., Chen I.S., Stevenson M., Tarpley W.G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 1993, 90:4713-4717.
32. Ehteshami M., Beilhartz G.L., Scarth B.J., Tchesnokov E.P., McCormick S., Wynhoven B., Harrigan P.R., Götte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J. Biol. Chem. 2008, 283:22222-22232.
33. El-Brollosy N.R., Jørgensen P.T., Dahan B., Boel A.M., Pedersen E.B., Nielsen C. Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants. J. Med. Chem. 2002, 45:5721-5726.
34. Eshleman S.H., Jones D., Galovich J., Paxinos E.E., Petropoulos C.J., Jackson J.B., Parkin N. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. AIDS Res. Hum. Retroviruses 2006, 22:289-293.
35. Esnouf R.M., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2:303-308.
36. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., Stuart D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this non-nucleoside inhibitor. Proc. Natl. Acad. Sci. USA 1997, 94:3984-3989.
37. Figueiredo A., Moore K.L., Mak J., Sluis-Cremer N., de Béthune M.P., Tachedjian G. Potent non-nucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog. 2006, 2:e119.
38. Fujihashi T., Hara H., Sakata T., Mori K., Higuchi H., Tanaka A., Kaji H., Kaji A. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39:2000-2007.
39. Fujiwara T., Sato A., el-Farrash M., Miki S., Abe K., Isaka Y., Kodama M., Wu Y., Chen L.B., Harada H., Sugimoto H., Hatanaka M., Hinuma Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42:1340-1345.
40. Gerondelis P., Archer R.H., Palaniappan C., Reichman R.C., Fay P.J., Bambara R.A., Demeter L.M. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J. Virol. 1999, 73:5803-5813.
41. Götte M., Kameoka M., McLellan N., Cellai L., Wainberg M.A. Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription. J. Biol. Chem. 2000, 276:6711-6719.
42. Grobler J.A., Dornadula G., Rice M.R., Simcoe A.L., Hazuda D.J., Miller M.D. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J. Biol. Chem. 2007, 282:8005-8010.
43. Gupta S., Fransen S., Paxinos E.E., Stawiski E., Huang W., Petropoulos C.J. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: Assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 2010, 54:1973-1980.
44. Gupta S., Vingerhoets J., Fransen S., Tambuyzer L., Azijn H., Frantzell A., Paredes R., Coakley E., Nijs S., Clotet B., Petropoulos C.J., Schapiro J., Huang W., Picchio G. Connection subdomain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob. Agents Chemother. 2011, 55:2872-2879.
45. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., Takiguchi M., Gatanaga H., Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 2008, 82:3261-3270.
46. Hachiya A., Shimane K., Sarafianos S.G., Kodama E.N., Sakagami Y., Negishi F., Koizumi H., Gatanaga H., Matsuoka M., Takiguchi M., Oka S. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. Antiviral Res. 2009, 82:115-121.
47. Hang J.Q., Li Y., Yang Y., Cammack N., Mirzadegan T., Klumpp K. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors. Biochem. Biophys. Res. Commun. 2007, 12:341-350.
48. Harrigan P.R., Salim M., Stammers D.K., Wynhoven B., Brumme Z.L., McKenna P., Larder B., Kemp S.D. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J. Virol. 2002, 76:6836-6840.
49. Harrigan P.R., Mo T., Wynhoven B., Hirsch J., Brumme Z., McKenna P., Pattery T., Vingerhoets J., Bacheler L.T. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005, 19:549-554.
50. Hsiou Y., Ding J., Das K., Clark A.D., Hughes S.H., Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4:853-860.
51. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 2003, 77:1512-1523.
52. Isaka Y., Miki S., Kawauchi S., Suyama A., Sugimoto H., Adachi A., Hayami M., Yoshie O., Fujiwara T., Sato A. Isolation and characterization of simian immunodeficiency virus variants that are resistant to nonnucleoside reverse transcriptase inhibitors. Arch. Virol. 2000, 145:2481-2492.
53. Isaka Y., Miki S., Kawauchi S., Suyama A., Sugimoto H., Adachi A., Miura T., Hayami M., Yoshie O., Fujiwara T., Sato A. A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch. Virol. 2001, 146:743-755.
54. Kagan R.M., Sista P., Pattery T., Bacheler L., Schwab D.A. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 2009, 23:1602-1605.
55. Kertesz D.J., Brotherton-Pleiss C., Yang M., Wang Z., Lin X., Qiu Z., Hirschfeld D.R., Gleason S., Mirzadegan T., Dunten P.W., Harris S.F., Villasenor A.G., Hang J.Q., Heilek G.M., Klumpp K. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Benzyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett. 2010, 20:4215-4218.
56. Kleim J.P., Winkler I., Rösner M., Kirsch R., Rübsamen-Waigmann H., Paessens A., Riess G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 1997, 231:112-118.
57. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
58. Lai M.T., Lu M., Felock P.J., Hrin R.C., Wang Y.J., Yan Y., Munshi S., McGaughey G.B., Tynebor R.M., Tucker T.J., Williams T.M., Grobler J.A., Hazuda D.J., McKenna P.M., Miller M.D. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2010, 54:4812-4824.
59. Lansdon E.B., Brendza K.M., Hung M., Wang R., Mukund S., Jin D., Birkus G., Kutty N., Liu X. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): Implications for drug design. J. Med. Chem. 2010, 53:4295-4299.
60. Lansdon E.B., Liu Q., Leavitt S.A., Balakrishnan M., Perry J.K., Lancaster-Moyer C., Kutty N., Liu X., Squires N.H., Watkins W.J., Kirschberg T.A. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob. Agents Chemother. 2011, 55:2905-2915.
61. Leigh Brown A.J., Precious H.M., Whitcomb J.M., Wong J.K., Quigg M., Huang W., Daar E.S., D'Aquila R.T., Keiser P.H., Connick E., Hellmann N.S., Petropoulos C.J., Richman D.D., Little S.J. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J. Virol. 2000, 74:10269-10273.
62. Lengruber R.B., Delviks-Frankenberry K.A., Nikolenko G.N., Baumann J., Santos A.F., Pathak V.K., Soares M.A. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J. Antimicrob. Chemother. 2011, 66:702-708.
63. Lindberg J., Sigurdsson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., Fridborg K., Zhang H., Unge T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 2002, 269:1670-1677.
64. Liu S., Abbondanzieri E.A., Rausch J.W., Le Grice S.F.J., Zhuang X. Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science 2008, 322:1092-1097.
65. Maga G., Amacker M., Ruel N., Hübscher U., Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274:738-747.
66. McCormick A.L., Parry C.M., Crombe A., Goodall R.L., Gupta R.K., Kaleebu P., Kityo C., Chirara M., Towers G.J., Pillay D. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob. Agents Chemother. 2011, 55:1806-1809.
67. Menéndez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 2008, 134:124-146.
68. Menéndez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 2010, 85:210-231.
69. Menéndez-Arias, L., 2011. Chapter 4: sensitivity to reverse transcriptase and protease inhibitors of recombinant HIV clones harboring resistance mutations: in vitro studies. In: Clotet, B., Menéndez-Arias, L., Schapiro, J.M., Kuritzkes, D., Burger, D., Rockstroh, J., Soriano, V., Telenti, A., Brun-Vezinet, F., Geretti, A.M., Boucher, C.A., Richman, D.D. (Eds.), The HIV & Hepatitis Drug Resistance and PK Guide, 11th ed., Fundació de Lluita contra la SIDA, Barcelona, Spain, pp. 171-333. Available from: <>http://www.flsida.org/theguide/.
70. Menéndez-Arias L., Abraha A., Quiñones-Mateu M.E., Mas A., Camarasa M.-J., Arts E.J. Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains. J. Biol. Chem. 2001, 276:27470-27479.
71. Molina J.-M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378:238-246. on behalf of the ECHO study group.
72. Nikolenko G.N., Palmer S., Maldarelli F., Mellors J.W., Coffin J.M., Pathak V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 2005, 102:2093-2098.
73. Nikolenko G.N., Delviks-Frankenberry K.A., Pathak V.K. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 2010, 84:5238-5249.
74. Olivares I., Mulky A., Boross P.I., Tözsér J., Kappes J.C., López-Galíndez C., Menéndez-Arias L. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions. J. Mol. Biol. 2007, 372:369-381.
75. Olmsted R.A., Slade D.E., Kopta L.A., Poppe S.M., Poel T.J., Newport S.W., Rank K.B., Biles C., Morge R.A., Dueweke T.J., Yagi Y., Romero D.L., Thomas R.C., Sharma S.K., Tarpley W.G. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J. Virol. 1996, 70:3698-3705.
76. Palaniappan C., Kim J.K., Wisniewski M., Fay P.J., Bambara R.A. Control of initiation of viral plus strand DNA synthesis by HIV reverse transcriptase. J. Biol. Chem. 1998, 273:3808-3816.
77. Paredes R., Puertas M.C., Bannister W., Kisic M., Cozzi-Lepri A., Pou C., Bellido R., Betancor G., Bogner J., Gargalianos P., Bánhegyi D., Clotet B., Lundgren J., Menéndez-Arias L., Martinez-Picado J. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J. Infect. Dis. 2011, 204:741-752. the EuroSIDA Study Group.
78. Parkin N.T., Gupta S., Chappey C., Petropoulos C.J. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2006, 50:351-354.
79. Pelemans H., Esnouf R., Dunkler A., Parniak M.A., Vandamme A.M., Karlsson A., De Clercq E., Kleim J.P., Balzarini J. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 1997, 71:8195-8203.
80. Pelemans H., Esnouf R.M., Jonckheere H., De Clercq E., Balzarini J. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 1998, 273:34234-34239.
81. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44:920-928.
82. Poveda E., de Mendoza C., Pattery T., González M.M., Villacian J., Soriano V. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008, 22:2395-2398.
83. Radzio J., Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 2008, 73:601-606.
84. Rao A., Balzarini J., Carbone A., Chimirri A., De Clercq E., Monforte A.M., Monforte P., Pannecouque C., Zappalà M. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res. 2004, 63:79-84.
85. Ren J., Stammers D.K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 2008, 134:157-170.
86. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2:293-302.
87. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000, 8:1089-1094.
88. Ren J., Nichols C., Bird L., Chamberlain P., Weaver K., Short S., Stuart D.I., Stammers D.K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 2001, 312:795-805.
89. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., Stammers D.K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 2004, 336:569-578.
90. Ren J., Nichols C.E., Stamp A., Chamberlain P.P., Ferris R., Weaver K.L., Short S.A., Stammers D.K. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J. 2006, 273:3850-3860.
91. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., Chan J.H., Kleim J.P., Stammers D.K. Relationship of potency and resilience to drug resistance mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J. Med. Chem. 2007, 50:2301-2309.
92. Richman D., Shih C.K., Lowy I., Rose J., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 1991, 88:11241-11245.
93. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shi C.-K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68:1660-1666.
94. Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., Woolf D.J., Debouck C., Harrison S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1995, 92:1222-1226.
95. Sato A., Hammond J., Alexander T.N., Graham J.P., Binford S., Sugita K., Sugimoto H., Fujiwara T., Patick A.K. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 2006, 70:66-74.
96. Schuckmann M.M., Marchand B., Hachiya A., Kodama E.N., Kirby K.A., Singh K., Sarafianos S.G. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J. Biol. Chem. 2010, 285:38700-38709.
97. Sluis-Cremer N., Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008, 134:147-156.
98. Sluis-Cremer N., Moore K., Radzio J., Sonza S., Tachedjian G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combinations with other resistance mutations. AIDS 2010, 24:317-319.
99. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., Steitz T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1994, 91:3911-3915.
100. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267:988-993.
101. Spence R.A., Anderson K.S., Johnson K.A. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry 1996, 35:1054-1063.
102. Su H.P., Yan Y., Prasad G.S., Smith R.F., Daniels C.L., Abeywickrema P.D., Reid J.C., Loughran H.M., Kornienko M., Sharma S., Grobler J.A., Xu B., Sardana V., Allison T.J., Williams P.D., Darke P.L., Hazuda D.J., Munshi S. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J. Virol. 2010, 84:7625-7633.
103. Tachedjian G., Orlova M., Sarafianos S.G., Arnold E., Goff S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 2001, 98:7188-7193.
104. Tambuyzer L., Azijn H., Rimsky L.T., Vingerhoets J., Lecocq P., Kraus G., Picchio G., de Béthune M.-P. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 2009, 14:103-109.
105. Venezia C.F., Howard K.J., Ignatov M.E., Holladay L.A., Barkley M.D. Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase. Biochemistry 2006, 45:2779-2789.
106. Vingerhoets J., Azijn H., Fransen E., De Baere I., Smeulders L., Jochmans D., Andries K., Pauwels R., de Béthune M.-P. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 2005, 79:12773-12782.
107. Xia Q., Radzio J., Anderson K.S., Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci. 2007, 16:1728-1737.
108. Yap S.-H., Sheen C.-W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4:1887-1900.
109. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carroll S.S., Pettibone D.J., O'Brien J.A., Ball R.G., Balani S.K., Lin J.H., Chen I.-W., Schleif W.A., Sardana V.V., Long W.J., Byrnes V.W., Emini E.A. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39:2602-2605.
110. Zhang Z., Xu W., Koh Y.-H., Shim J.H., Girardet J.-L., Yeh L.-T., Hamatake R.K., Hong Z. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2007, 51:429-437.